NASDAQ · WVE
Healthcare · Biotechnology
$3.52
Down-$0.23 (-6.13%)
Updated Oct 7, 2026, 3:47 AM
SID Score
3.6/10
Composite research score
Smart Money
58/100
Neutral
Price performance · WVE
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
WVE closed at $3.52 after 21 trading sessions, down 28.31% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $3.78 | $3.815 | $3.4815 | $3.52 | 3.45M |
| Oct 5, 2026 | $3.81 | $3.88 | $3.705 | $3.75 | 3.51M |
| Oct 2, 2026 | $3.89 | $3.96 | $3.77 | $3.78 | 3.75M |
| Oct 1, 2026 | $3.95 | $4.07 | $3.775 | $3.88 | 5.42M |
| Sep 30, 2026 | $3.79 | $3.84 | $3.62 | $3.70 | 4.21M |
| Sep 29, 2026 | $3.67 | $3.779 | $3.555 | $3.64 | 2.77M |
| Sep 28, 2026 | $3.77 | $3.78 | $3.60 | $3.67 | 3.55M |
| Sep 25, 2026 | $4.00 | $4.00 | $3.745 | $3.78 | 4.07M |
| Sep 24, 2026 | $3.96 | $4.0053 | $3.82 | $3.96 | 3.16M |
| Sep 23, 2026 | $4.27 | $4.35 | $3.9201 | $3.95 | 3.98M |
| Sep 22, 2026 | $4.30 | $4.43 | $4.22 | $4.35 | 2.58M |
| Sep 21, 2026 | $4.44 | $4.45 | $4.20 | $4.255 | 2.37M |
| Sep 18, 2026 | $4.42 | $4.475 | $4.31 | $4.35 | 4.41M |
| Sep 17, 2026 | $4.59 | $4.645 | $4.42 | $4.44 | 2.17M |
| Sep 16, 2026 | $4.55 | $4.60 | $4.42 | $4.505 | 2.99M |
| Sep 15, 2026 | $4.58 | $4.58 | $4.40 | $4.46 | 2.47M |
| Sep 14, 2026 | $4.60 | $4.63 | $4.49 | $4.58 | 2.87M |
| Sep 11, 2026 | $4.67 | $4.72 | $4.56 | $4.59 | 2.21M |
| Sep 10, 2026 | $4.76 | $4.76 | $4.63 | $4.67 | 2.77M |
| Sep 9, 2026 | $4.86 | $4.9297 | $4.76 | $4.81 | 3.25M |
| Sep 8, 2026 | $4.86 | $4.965 | $4.75 | $4.91 | 3.56M |
The latest Smart Investors Daily articles mentioning WVE.
Company
Market Activity
Research & News
WVE research
Company profile and research snapshot.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 1, 2026 | Ladenburg Thalmann | Buy | — |
| Sep 23, 2026 | JP Morgan | Neutral | — |
| Aug 4, 2026 | Mizuho | Outperform | — |
| Jul 31, 2026 | B. Riley Securities | Buy | — |
| Jul 31, 2026 | Wedbush | Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 1, 2026
The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
Yahoo · Oct 1, 2026
Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers WVE-006 (RNA editing) has potential to offer the AATD community a new standard-of-care treatment to protect the liver and lung with a safe and convenient therapy CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad
Benzinga · Oct 1, 2026
Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced alignment with the U.S. Food and Drug
Yahoo · Sep 30, 2026
Candidate selected by GSK utilizes Wave’s best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that as part of the companies’ research collaboration, GSK has selected a candidate for a hepatology
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning WVE.
